User:Mr. Ibrahem/Cariprazine

Cariprazine, sold under the brand names Vraylar and Reagila, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder. It is taken by mouth. Use is not recommended by Wales.

Common side effects include movement disorders, heart burn, sleepiness, and restlessness. Other side effects may include neuroleptic malignant syndrome, tardive dyskinesia, diabetes, weight gain, low white blood cells, low blood pressure with standing, and seizures. Use in older people with dementia increase the risk of death. Safety in pregnancy is unclear. It acts primarily on dopamine and serotonin receptors.

Cariprazine was approved for medical use in the United States in 2015 and Europe in 2017. In the United Kingdom 4 weeks of treatment costs the NHS about £80 as of 2021. This amount in the United States costs about 1,250 USD.